FIG 5.
Liquid biopsy mutation correlation to response rate as calculated by change in radiologic response (RECIST 1.1) versus change in mutation molecules, representative of tumor mutation burden, after first-line platinum-based chemotherapy in an unselected cohort with advanced non–small-cell lung cancer (n = 31). Data from 20 patients are shown; others lacked baseline genomic alterations or RECIST data. (*) Two data points, with overlapping data. ctDNA, circulating tumor DNA. D42, day 42.